The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Claims

16 · 3 independent · depth 4

16 granted claims

›1.independentA compound having the structural formula: ##STR4## or a pharmaceutically acceptable salt or hydrate thereof, wherein: The bond - - - designates a sing…+1

A compound having the structural formula: ##STR4## or a pharmaceutically acceptable salt or hydrate thereof, wherein: The bond - - - designates a single or double bond; m is 0, 1, 2, 3 or 4; each n is independently 0, 1, 2, 3, 4 or 5; Y is absent, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl or (C.sub.1 -C.sub.6) alkynyl; R.sub.1 is H, --OR, --SR, --O--C(O)R, --S--C(O)R, --O--C(S)R, --S--C(S)R, or when taken together with R.sub.2 is a .dbd.O, .dbd.S, .dbd.N--OR, a 3-8 membered heterocycloalkyl or a substituted 3-8 membered heterocycloalkyl; R.sub.2 is absent or --H; R.sub.3 is absent or --H; R.sub.4 is --H, --OR', --SR', --NR'.sub.2, --CN, --NO.sub.2, (C.sub.3 -C.sub.8) cycloalkyl, 3-8 membered heterocycloalkyl, --C(O)R', --C(S)R', --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR', C(O)NR'.sub.2 or --C(S)NR'.sub.2 ; each R.sub.5, R.sub.6 and R.sub.7 is independently selected from the group consisting of halogen, --R', --OR', --SR', --NR'.sub.2, --ONR'.sub.2, --SNR'.sub.2, --NO.sub.2, --CN, --C(O)R', --C(S)R', --C(O)OR', --C(O)SR', --C(S)OR', --CS(S)R', --C(O)NR'.sub.2, --C(S)NR'.sub.2, --C(O)NR'(OR'), --C(S)NR'(OR'); --C(O)NR'(SR'), --C(S)NR'(SR'), --CH(CN).sub.2, --CH[C(O)R'].sub.2, --CH[C(S)R'].sub.2, --CH[C(O)OR'].sub.2, --CH[C(S)OR'].sub.2, --CH[C(O)SR'].sub.2 and --CH[C(S)SR'].sub.2 ; with the following exceptions: when - - - is single bond, R.sub.1 and R.sub.2 when taken together are .dbd.O, Y is absent, R.sub.3 and R4 are H, m=0, n=1; then (a) if R.sub.5 is absent. then R.sub.6 is not Br (para), or OMe (para) or OH (para); (b) if R.sub.5 is OH (para) then R.sub.6 is not --NMe.sub.2 at the para position; or when - - - is single bond, both R.sub.1 and R.sub.2 are H, Y is absent, R.sub.3 and R4 both are H, m=0; (a) then n is not 0; and (b) if n is 1, then both R.sub.5 and R.sub.6 are not --NH.sub.2 at para positions; (c) if n is 1, then both R.sub.5 and R.sub.6 are not --OH at the para position; or when - - - is double bond, Y, R.sub.2 and R.sub.3 are absent, R.sub.1 and R.sub.4 are H, m=0; (a)then n is not 0; (b) if n is 1, R.sub.5 is absent, then R.sub.6 is not --OMe (para), or Br (para), or --CN (para); or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.O, Y is absent, R.sub.3 is Me, R.sub.4 is 1, m=0, n=1, then both R.sub.5 and R.sub.6 are not --OH at the para position; or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.O, Y is absent, R.sub.3 is --C(O)OEt, R.sub.4 is H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --OH at the para position; or when - - - is single bond, R.sub.1 is --OH, R.sub.2 is H, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.N--OH.HCl, Y is absent, R.sub.3 and R.sub.4 are H, m=0, then n is not 0; and each R is independently selected from the group consisting of --H, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl, (C.sub.1 -C.sub.6) alkynyl, (C.sub.5 -C.sub.20) aryl, substituted (C.sub.5 -C.sub.20) aryl, (C.sub.6 -C.sub.26) alkaryl and substituted (C.sub.6 -C.sub.26) alkaryl; the heterocycloalkyl substituents are each independently selected from the group consisting of --CN, --NO.sub.2, --NR'.sub.2, --OR', --C(O)NR'.sub.2, --C(S)NR'.sub.2, --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR' and trihalomethyl; the aryl substituents are each independently selected from the group consisting of halogen, --C(O)R', --C(S)R', --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR', --C(O)NR'.sub.2, --C(S)NR'.sub.2 and trihalomethyl; each R' is independently selected from the group consisting of --H, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl and (C.sub.1 -C.sub.6) alkynyl.

›3.independentA pharmaceutical composition comprising an effective amount of a compound and a pharmaceutically acceptable excipient, carrier or diluent, said compou…+9

A pharmaceutical composition comprising an effective amount of a compound and a pharmaceutically acceptable excipient, carrier or diluent, said compound having the structural formula (I): or a pharmaceutically acceptable salt or hydrates thereof, wherein: --- designates a single or double bond; m is 0, 1, 2, 3 or 4; Y is absent, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl or (C.sub.1 -C.sub.6) alkynyl; R.sub.1 is H, --OR, --SR,, --O--C(O)R, --S--C(O)R, --O--C(S)R, --S--C(S)R, or when taken together with R.sub.2 is .dbd.O, .dbd.S, .dbd.N--OR, a 3-8 membered heterocycloalkyl or a substituted 3-8 membered heterocycloalkyl; R.sub.2 is absent or --H; R.sub.3 is absent or --H; R.sub.4 is --H, --OR', --SR', --NR'.sub.2, --CN, --NO.sub.2, (C.sub.3 -C.sub.8) cycloalkyl, 3-8 membered heterocycloalkyl, --C(O)R', --C(S)R', --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR', --C(O)NR'.sub.2 or --C(S)NR'.sub.2 ; each R.sub.5, R.sub.6 and R.sub.7 is independently selected from the group consisting of halogen, --R', --OR', --SR', --NR'.sub.2, --ONR'.sub.2, --SNR'.sub.2, --NO.sub.2, --CN, --C(O)R', --C(S)R', --C(O)OR', --C(O)SR', --C(S)OR', --CS(S)R', --C(O)NR'.sub.2, --C(S)NR'.sub.2, --C(O)NR'(OR'), --C(S)NR'(OR'); --C(O)NR'(SR'), --C(S)NR'(SR'), --CH(CN).sub.2, --CH[C(O)R'].sub.2, --CH[C(S)R'].sub.2, --CH[C(O)OR'].sub.2, --CH[C(S)OR'].sub.2, --CH[C(O)SR'].sub.2 and --CH[C(S)SR'].sub.2 ; with the following exceptions: when - - - is single bond, R.sub.1 and R.sub.2 when taken together are .dbd.O, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1; then (a) if R.sub.5 is absent, then R.sub.6 is not Br (para), or OMe (para) or OH (para); (b) if R.sub.5 is OH (para) then R.sub.6 is not --NMe.sub.2 at the para position; or when - - - is single bond, both R.sub.1 and R.sub.2 are H, Y is absent, R.sub.3 and R.sub.4 both are H, m=0; (a) then n is not 0; and (b) if n is 1, then both R.sub.5 and R.sub.6 are not --NH.sub.2 at para positions; (c) if n is 1, then both R.sub.5 and R.sub.6 are not --OH at the para position; or when - - - is double bond, Y, R.sub.2 and R.sub.3 are absent, R.sub.1 and R.sub.4 are H, m=0; (a)then n is not 0; (b) if n is 1, R.sub.5 is absent, then R.sub.6 are is --OMe (para), or Br (para), or --CN (para); or when - - - is single bond, RI and R.sub.2 taken together are .dbd.O, Y is absent, R.sub.3 is Me, R.sub.4 is H, m=0, n=1, then both R.sub.5 and R.sub.6 are not --OH at the para position; or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.O, Y is absent, R.sub.3 is --C(O)OEt, R.sub.4 is H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --OH at the para position; or when - - - is single bond, R.sub.1 is --OH, R.sub.2 is H, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.N--OH.HCl, Y is absent, R.sub.3 and R4 are H, m=0, then n is not 0; and each R is independently selected from the group consisting of --H, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl, (C.sub.1 -C.sub.6) alkynyl, (C.sub.5 -C.sub.20) aryl, substituted (C.sub.5 -C.sub.20) aryl, (C.sub.6 -C.sub.26) alkaryl and substituted (C.sub.6 -C.sub.26) alkaryl; the heterocycloalkyl substituents are each independently selected from the group consisting of --CN, --NO.sub.2, --NR'.sub.2, --OR', --C(O)NR'.sub.2, --C(S)NR'.sub.2, --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR' and trihalomethyl; the aryl and alkaryl substituents are each independently selected from the group consisting of halogen, --C(O)R', --C(S)R', --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR', --C(O)NR'.sub.2, --C(S)NR'.sub.2 and trihalomethyl; each R' is independently selected from the group consisting of --H, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl and (C.sub.1 -C.sub.6) alkynyl.

›4.↳ 3The pharmaceutical composition of claim 3, wherein in the compound of structural formula (I): ##STR6## --- is a single or double bond; m is 0 or 1; ea…d2+1

The pharmaceutical composition of claim 3, wherein in the compound of structural formula (I): ##STR6## --- is a single or double bond; m is 0 or 1; each n is independently 0 or 1; Y is absent, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl or (C.sub.1 -C.sub.3) alkynyl; R.sub.1 is --H, --OR, --O--C(O)R, or when taken together with R.sub.2 is .dbd.O, --NR.sub.2, .dbd.N--OR, a 3-5 membered oxirane or 3-5 membered substituted oxirane; R.sub.2 is absent or --H; R.sub.3 is absent or --H; R.sub.4 is --H, --OR, --NR.sub.2, --CN, --C(O)OR, --C(O)NR.sub.2 or 5-6 membered dioxoycycloalkyl; each R.sub.5, R.sub.6 and R.sub.7 is independently selected from the group consisting of --R', --F, --Cl or --Br; with the following exceptions: when - - - is single bond, R.sub.1 and R.sub.2 when taken together are .dbd.O, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1; and if R.sub.5 is absent, then R.sub.6 is not Br at the para position; or when - - - is single bond, both R.sub.1 and R.sub.2 are H, Y is absent, R.sub.3 and R.sub.4 both are H, m=0; then n is not 0; or when - - - is double bond, Y, R.sub.2 and R.sub.3 are absent, R.sub.1 and R.sub.4 are H, m=0; then n is not 0; (b) if n is 1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; or when - - - is single bond, R.sub.1 is --OH, R.sub.2 is H, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; each R is independently selected from the group consisting of --H, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl, (C.sub.1 -C.sub.3) alkynyl, (C.sub.5 -C.sub.10) aryl, substituted (C.sub.5 -C.sub.10) aryl, (C.sub.6 -C.sub.13) alkaryl, substituted (C.sub.6 -C.sub.13) alkaryl; the oxirane substituent is --CN, --NO.sub.2, --NR'.sub.2, --OR' and trihalomethyl; the aryl and alkaryl substituents are each independently selected from the group consisting of --F, --Cl, --Br, --CN, --NO.sub.2, --NR'.sub.2, --C(O)R', --C(O)OR' and trihalomethyl; R' is --H, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl or (C.sub.1 -C.sub.3) alkynyl.

›10.↳ 3A method of treating or preventing a disorder characterized by abnormal cell proliferation, said method comprising the step of administering to a subj…d2+6

›11.↳ 10The method of claim 10, wherein in the compound of structural formula (I): --- is a single or double bond; m is 0 or 1; each n is independently 0 or 1…d3+1

The method of claim 10, wherein in the compound of structural formula (I): --- is a single or double bond; m is 0 or 1; each n is independently 0 or 1; Y is absent, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl or (C.sub.1 -C.sub.3) alkynyl; R.sub.1 is --H, --OR, --O--C(O)R, or when taken together with R.sub.2 is .dbd.O, --NR.sub.2, .dbd.N--OR, or a 3-5 membered oxirane or 3-5 membered substituted oxirane; R.sub.2 is absent or --H; R.sub.3 is absent or --H; R.sub.4 is --H, --OR, --NR.sub.2, --CN, --C(O)OR, --C(O)NR.sub.2 or 5-6 membered dioxoycycloalkyl; each R.sub.5, R.sub.6 and R.sub.7 is independently selected from the group consisting of --R', --F, --Cl or --Br; with the following exceptions: when - - - is single bond, R.sub.1 and R.sub.2 when taken together are .dbd.O, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1; and if R.sub.5 is absent, then R.sub.6 is not Br at the para position; or when - - - is single bond, both R.sub.1, and R.sub.2 are H, Y is absent, R.sub.3 and R.sub.4 both are H, m=0; then n is not 0; or when - - - is double bond, Y, R.sub.2 and R.sub.3 are absent, R.sub.1 and R.sub.4 are H, m=0; then n is not 0; (b) if n is 1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; or when - - - is single bond, R.sub.1 is --OH, R.sub.2 is H, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; each R is independently selected from the group consisting of --H, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl, (C.sub.1 -C.sub.3) alkynyl, (C.sub.5 -C.sub.10) aryl, substituted (C.sub.5 -C.sub.10) aryl, (C.sub.6 -C.sub.13) alkaryl, substituted (C.sub.6 -C.sub.13) alkaryl; the oxirane substituent is --CN, --NO.sub.2, --NR'.sub.2, --OR' and trihalomethyl; the aryl and alkaryl substituents are each independently selected from the group consisting of --F, --Cl, --Br, --CN, --NO.sub.2, --NR'.sub.2, --C(O)R', --C(O)OR' and trihalomethyl; R' is --H, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl or (C.sub.1 -C.sub.3) alkynyl.

›13.↳ 10The method of claim 10, wherein said disease characterized by abnormal cell proliferation is cancer, a blood vessel proliferative disorder, a fibrotic…d3+1

›15.↳ 10The method of claim 10, wherein said disease characterized by abnormal cell proliferation is a dermatological disease or Kaposi's sarcoma and said adm…d3+1

›6.independentA method of inhibiting mammalian cell proliferation, said method comprising the step of contacting a mammalian cell in situ with an effective amount o…+3

A method of inhibiting mammalian cell proliferation, said method comprising the step of contacting a mammalian cell in situ with an effective amount of a compound having the structural formula: or a pharmaceutically acceptable salt or hydrate thereof, wherein: --- designates a single or double bond; m is 0, 1, 2, 3 or 4; Y is H, --OR, --SR, --O--C(O)R, --S--C(O)R, --O--C(S)R, --S--C(S)R, or when taken together with R.sub.2 is .dbd.O, .dbd.S, .dbd.N--OR, a 3-8 membered heterocycloalkyl or a substituted 3--8 membered heterocycloalkyl; R.sub.2 is absent or --H; R.sub.3 is absent or --H; R.sub.4 is --H, --OR', --SR', --NR'.sub.2, --CN, --NO.sub.2, (C.sub.3 -C.sub.8) cycloalkyl, 3-8 membered heterocycloalkyl, --C(O)R', --C(S)R', --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR', --C(O)NR'.sub.2 or --C(S)NR'.sub.2 ; each R.sub.5, R.sub.6 and R.sub.7 is indepedently selected from the group consisting of -halogen, --R', --OR', --SR', --NR'.sub.2, --ONR'.sub.2, --SNR'.sub.2, --NO.sub.2, --CN, --C(O)R', --C(S)R', --C(O)OR', --C(O)SR', --C(S)OR', --CS(S)R', --C(O)NR'.sub.2, --C(S)NR'.sub.2, --C(O)NR'(OR'), --C(S)NR'(OR'); --C(O)NR'(SR'), --C(S)NR'(SR'), --CH(CN).sub.2, --CH[C(O)R'].sub.2, --CH[C(S)R'].sub.2, --CH[C(O)OR'].sub.2, --CH[C(S)OR'].sub.2, --CH[C(O)SR'].sub.2 and --CH[C(S)SR'].sub.2 ; with the following exceptions: when - - - is single bond, RI and R.sub.2 when taken together are .dbd.O, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1; then (a) if R.sub.5 is absent, then R.sub.6 is not Br (para), or OMe (para) or OH (para); (b) if R.sub.5 is OH (para) then R.sub.6 is not --NMe.sub.2 at the para position; or when - - - is single bond, both R.sub.1 and R.sub.2 are H, Y is absent, R.sub.3 and R.sub.4 both are H, m=0; (a) then n is not 0; and (b) if n is 1, then both R.sub.5 and R.sub.6 are not --NH.sub.2 at para positions; (c) if n is 1, then both R.sub.5 and R.sub.6 are not --OH at the para position; or when - - - is double bond, Y, R.sub.2 and R.sub.3 are absent, R.sub.1 and R.sub.4 are H, m=0; (a) then n is not 0; (b) if n is 1, R.sub.5 is absent, then R.sub.6 are is --OMe (para), or Br (para), or --CN (para); or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.O, Y is absent, R.sub.3 is Me, R.sub.4 is H, m=0, n=1, then both R.sub.5 and R.sub.6 are not --OH at the para position; or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.O, Y is absent, R.sub.3 is --C(O)OEt, R.sub.4 is H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --OH at the para position; or when - - - is single bond, R.sub.1 is --OH, R.sub.2 is H, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; or when - - - is single bond, R.sub.1 and R.sub.2 taken together are .dbd.N--OH.HCl, Y is absent, R.sub.3 and R.sub.4 are H, m=0, then n is not 0; and each R is independently selected from the group consisting of --H, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl, (C.sub.1 -C.sub.6) alkynyl, (C.sub.5 -C.sub.20) aryl, substituted (C.sub.5 -C.sub.20) aryl, (C.sub.6 -C.sub.26) alkaryl and substituted (C.sub.6 -C.sub.26) alkaryl; the heterocycloalkyl substituents are each independently selected from the group consisting of --CN, --NO.sub.2, --NR'.sub.2, --OR', --C(O)NR'.sub.2, --C(S)NR'.sub.2, --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR' and trihalomethyl; the aryl and alkaryl substituents are each independently selected from the group consisting of halogen, --C(O)R', --C(S)R', --C(O)OR', --C(S)OR', --C(O)SR', --C(S)SR', --C(O)NR'.sub.2, --C(S)NR'.sub.2 and trihalomethyl; each R' is independently selected from the group consisting of --H, (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkenyl and (C.sub.1 -C.sub.6) alkynyl.

›7.↳ 6T he method of claim 6, wherein in the compound of structural formula (1): --- is a single or double bond; m is 0 or 1; Y is absent, (C.sub.1 -C.sub.3…d2+1

T he method of claim 6, wherein in the compound of structural formula (1): --- is a single or double bond; m is 0 or 1; Y is absent, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl or (C.sub.1 -C.sub.3) alkynyl; R.sub.1 is --H, --OR, --O--C(O)R, or when taken together with R.sub.2 is .dbd.O, --NR.sub.2, .dbd.N--OR, 3-5 membered oxirane or 3-5 membered substituted oxirane; R.sub.2 is absent or --H; R.sub.3 is absent or --H; R.sub.4 is --H, --OR, --NR.sub.2, --CN, --C(O)OR, --C(O)NR.sub.2, or 5-6 membered dioxoycycloalkyl; each R.sub.5, R.sub.6 and R.sub.7 is independently selected from the group consisting of --R', --F, --Cl or --Br; with the following exceptions: when - - - is single bond, R.sub.1 and R.sub.2 when taken together are .dbd.O, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1; and if R.sub.5 is absent, then R.sub.6 is not Br at the para position; or when - - - is single bond, both R.sub.1 and R.sub.2 are H, Y is absent, R.sub.3 and R.sub.4 both are H, m=0; then n is not 0; or when - - - is double bond, Y, R.sub.2 and R.sub.3 are absent, R.sub.1 and R.sub.4 are H, m=0; then n is not 0; (b) if n is 1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; or when - - - is single bond, R.sub.1 is OH, R.sub.2 is H, Y is absent, R.sub.3 and R.sub.4 are H, m=0, n=1, R.sub.5 is absent, then R.sub.6 is not --Br at the para position; each R is independently selected from the group consisting of --H, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkenyl, (C.sub.1 -C.sub.3) alkynyl, (C.sub.5 -C.sub.10) aryl, substituted (C.sub.5 -C.sub.10) aryl, (C.sub.6 -C.sub.13) alkaryl, substituted C.sub.6 -C.sub.13) alkaryl; the oxirane substituent is --CN, --NO.sub.2, --NR'.sub.2, --OR' and trihalomethyl; the aryl and alkaryl substituents are each independently selected from the group consisting of --F, --Cl, --Br, --CN, --NO.sub.2, --NR'.sub.2, --C(O)R', --C(O)OR' and trihalomethyl; R' is --H, (C.sub.1 -C.sub.3) alkenyl (C.sub.1 -C.sub.3) alkenyl or (C.sub.1 -C.sub.3) alkynyl.

›9.↳ 6The method of claim 6, wherein said mammalian cell is an endothelial cell, a fibrotic cell or a vascular smooth muscle cell.d2

Classifications

19 codes

USPC · US Patent Classification

514/467514/475560/57514/546549/430514/640560/221564/265568/808514/544568/809560/56514/617558/388564/180549/550568/659514/717549/453

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

2.9 y

1,048 days filing → grant

Office actions

on the grant's record

Examiner

Mukund J. Shah

art unit —

Law firm

Law firm · Log in to unlock

Citations: 13 back · 0 forward

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.